ZeClinics has been selected to perform an essential inter-laboratory study sponsored by SEAZIT Barcelona, Spain. ZeClinics, a biotech firm focused on preclinical services with zebrafish, has been selected to perform a critical inter-laboratory study sponsored by the SEAZIT program (Systematic Evaluation of the Application of Zebrafish in Toxicology). Health © zeclinics SEAZIT was established by the National Toxicology Program (NTP) of the National Institutes of Health (NIH), and it is led jointly by NTP and NICEATM scientists (NTP Interagency Center for the Evaluation of Alternative Toxicological Methods). The objective of SEAZIT focuses on the development of best practices for data analysis. Following this line, all the data obtained through this study will be made public, so researchers can use it in the future to assess the toxicity consensus values for each chemical tested. The specific aim of this project, in which ZeClinics will participate, is to identify relevant sources of variability to draft a new and better-standardized protocol for fish embryos acute toxicity assays. To do so, ZeClinics will assess the toxicological and teratogenic impact of 38 chemicals under different conditions using zebrafish embryos. The small size and rapid development of the zebrafish make it very useful to assess the potential effects of substances on growth and development using high-throughput screening methods. “Participating in this project is a great opportunity to demonstrate the validity and robustness of the zebrafish in the field of toxicology,” said Dr. Davide D’Amico, Co-Founder and CEO at ZeClinics. He continues, “Currently there is a powerful social impulse aimed at the acceptance of alternative models in biomedical research such as the zebrafish. We are very honored because, with initiatives like this, we are part of this revolution”. This project has been funded in whole or in part with Federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services. Battelle Memorial Institute, located in Columbus, Ohio, serves as prime contractor. About Zeclinics SL: ZeClinics is an innovative biotech firm committed to streamlining discovery and preclinical development of novel compounds with zebrafish, an ideal vertebrate model for fast, cost-effective, and highly predictive assessments. ZeClinics combines in-house academic expertise with a diversified, cutting-edge portfolio: from CRISPR-licensed gene editing, high-throughput safety and efficacy assays to disease models. For more information, please visit www.zeclinics.com or contact ZeClinics. Keywords zebrafish, toxicology, validation, regulation, NIH, SEAZIT, NTP, NICEATM
